Sanofi and Xinji acquired biooverativ and Juno respectively

Source: U.S - Sinopharm 2018-01-23 [news event]: Sanofi purchased hemophilia manufacturer biooverativ with a 64% premium of US $11.6 billion this morning, while Xinji purchased car-t drug manufacturer Juno with us $9 billion Xinji has bought 9.7% of Juno shares in 2015, and today it has acquired the rest Sanofi acquired mdvn the year before and actelion last year, which was intercepted by Pfizer and Johnson & Johnson, and finally completed a 10 billion plus deal However, investors are not enthusiastic, and today's shares are down 3% The new base / Juno deal also failed to see Geely celebrating its acquisition of kit, another car-t company, last year Today, the shares of new base have hardly changed [drug source analysis]: Sanofi has enjoyed the market of rare diseases since its acquisition of keyzan Hemophilia is one of the most profitable rare diseases This year Sanofi acquired all rights and interests in the development of RNAi hemophilia drug fitusiran in cooperation with Alnylam Today's acquisition is obviously to consolidate its position in this market Bivv was separated from Baijian last year, when it was only $40 per share A year's increase of 2.5 times indicates that it was a correct decision for Baijian to divest bivv at that time It was worth more to sell chicken claws and breast separately than the whole chicken The main products of bivv are coagulation factor eloctate and alprolix, which is a mature specialized drug enterprise But one product line, tnt009, which was acquired by US $400 million last year, is in phase III clinic, and there is also a thalassemia gene therapy ST401, which is still in preclinical stage Xinji is a pharmaceutical factory with the core mode of acquiring early assets, which is another big move after the 7 billion acquisition of impact biomedicines this year Xinji has participated in the investment of Juno and Bluebird, another car-t enterprise Although Juno was acquired today, Xinji still said that bb2121 with bluebird is the top priority asset The main domain of bb2121 is hematoma, especially multiple myeloma As the end-line therapy, bb2121 is more effective and safer than car-t of CD19 Although Juno's BCMA assets are somewhat similar to those of bb2121, it makes sense for a blood tumor company to acquire a car-t company under the pressure of heavy drugs about to expire Sanofi used to focus on diabetes and cardiovascular diseases It was once listed on the market as the drug king and heavyweight insulin product Lantus, and now it has transferred to specialized rare diseases Xinji has been a specialized disease enterprise, but its main asset is stop reaction derivative, which is different from car-t in technical content At present, car-t is only limited to terminal blood tumor Although there are more opportunities for Gilead and Xinji to enter solid tumor, no one can guarantee it Hemophilia is a rapidly changing market Not only was Roche's bispecific antibody hemlibra on the market last year, but also spark and biomarin's gene therapy showed nearly 100% efficacy This may produce a cure product, and it is sooner or later that the clotting factor product is replaced So these two acquisitions are two different kinds of gambling Sanofi expects old Huang Zhong to fight a few more battles even though he is not strong enough Xinji hopes young commander can unify the Jianghu as soon as possible though there are many things to prove Car-t and gene therapy undoubtedly represent the future, but influenced by factors such as price, convenience of use and familiarity of doctors, the market penetration of approved car-t drugs and gene therapy is slow Although bivv's product lines are mature products and will be overturned sooner or later, the schedule is unpredictable and may provide several years of valuable cash flow for Sanofi Poetry and distance are important, but the cost of living this month has to be settled This is similar to the transportation industry in the early 20th century Although the white brothers have successfully flown, the carriage is still a profitable means of transportation Last year's only big acquisition of Biopharmaceutics was Geely's 12 billion acquisition of kit, and today's morning market saw a $20 billion change of hands January hasn't finished this year, but in addition to today's deal, there were rumors last week that Novo Nordisk was bidding for acorda for Ablynx, Parkson and UCB The urgent need for new products by pharmaceutical companies is the main driving force for the acquisition, but in recent times, the control of drug prices has been relaxed, and the reduction of corporate tax in the United States is also an auxiliary factor.